Pulmonary surfactant synthesis machinery

The pulmonary surfactant synthesis machinery in type II pneumocytes is a complex biological system responsible for the production, storage, and secretion of the surfactant film that lines the alveoli. This system is composed of approximately 90% lipids (primarily dipalmitoylphosphatidylcholine) and 10% specialized proteins, including the hydrophobic proteins SP-B and SP-C, and the hydrophilic collectins SP-A and SP-D (StatPearls, 2023). The machinery involves a coordinated sequence of phospholipid biosynthesis, protein translation, and assembly within specialized organelles known as lamellar bodies, facilitated by transporters such as ABCA3 (UniProt, 2024). Dysfunction in this machinery, whether due to prematurity or genetic mutations in components like SFTPB or ABCA3, leads to Neonatal Respiratory Distress Syndrome (NRDS) and chronic interstitial lung diseases (NIH, 2023). Pharmacological management focuses on stimulating the machinery using antenatal glucocorticoids to induce gene expression or bypassing the machinery through the administration of exogenous surfactant replacements to restore alveolar stability and gas exchange (PubMed, 2022).

Other names

Surfactant production systemType II pneumocyte surfactant pathwayPulmonary surfactant systemAlveolar surfactant machinery

Glucocorticoid receptor agonists induce the transcription of surfactant-associated genes and enzymes to accelerate lung maturation. Exogenous surfactant replacements provide a direct supply of phospholipids and hydrophobic proteins (SP-B and SP-C) to the alveolar surface to reduce surface tension and prevent atelectasis (StatPearls, 2023).